Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PRO-513 Clear all
Completed Phase 2 Interventional Results available

Bonipar for Acute and Chronic Musculoskeletal Pain

NCT03471507
View directory record Official record
Conditions
Chronic Pain, Musculoskeletal Pain
Interventions
Bonipar, Diclofenac sodium topical solution 1.5%
Drug
Lead sponsor
Winston Parris, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

NCT02132247
View directory record Official record
Conditions
Athletic Injuries
Interventions
Diclofenac hydroxyethylpyrrolidine
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
6 Years to 16 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

NCT01596647
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
caffeine, diclofenac, omeprazole, midazolam, TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 6, 2026, 5:34 AM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Miami, Florida • Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT05882812
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 6, 2026, 5:34 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis

NCT07515872
View directory record Official record
Conditions
Arthritis, Osteo Arthritis of the Knee
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, Intra articular injection
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Stamford, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

NCT04683627
View directory record Official record
Conditions
Osteoarthritis Pain of the Knee
Interventions
Diclofenac sodium active topical patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Doral, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute

NCT01982539
View directory record Official record
Conditions
Pain
Interventions
Zipsor®
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Sheffield, Alabama • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 6, 2026, 5:34 AM EDT
Not listed Phase 3 Interventional

ACL-R Opioid Sparing Study

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

NCT02424578
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Diclofenac Capsules low dose, Diclofenac Capsules high dose
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Sheffield, Alabama • Little Rock, Arkansas • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

NCT06693648
View directory record Official record
Conditions
Osteoarthritis of Knee, Osteoarthritis, Knee
Interventions
AMZ001 Diclofenac gel, Placebo gel
Drug
Lead sponsor
Amzell
Industry
Eligibility
40 Years to 85 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Thousand Oaks, California • Hialeah, Florida • Longwood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 4 Interventional

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

NCT00595543
View directory record Official record
Conditions
Acute Pseudophakic Cystoid Macular Edema
Interventions
Bromfenac, Ketorolac, Diclofenac
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products

NCT01592019
View directory record Official record
Conditions
Bioequivalence
Interventions
Reference, Patch location thigh, batch 1, Test, Patch location thigh, batch 2, Reference, Patch location abdomen, batch 1, Test, Patch location abdomen, batch 2
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

NCT02169154
View directory record Official record
Conditions
Pain
Interventions
1% Diclofenac Sodium, 3% Menthol, 0.09% Menthol, 0.2% Sodium Lauryl Sulfate, 0.9% Saline
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

NCT03826550
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo
Drug · Other
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 6, 2026, 5:34 AM EDT
Not listed Phase 4 Interventional

IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine

NCT02664116
View directory record Official record
Conditions
Migraine Headache
Interventions
Diclofenac postassium powder for oral solution and placebo injection, Ketorolac intramuscular injection and placebo oral solution
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

NCT02290821
View directory record Official record
Conditions
Acute Blunt Soft Tissue Injuries/Contusions
Interventions
placebo, Placebos
Drug
Lead sponsor
Novartis
Industry
Eligibility
16 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Bradenton, Florida • Port Orange, Florida • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

NCT05968482
View directory record Official record
Conditions
Healthy
Interventions
Diclofenac Sodium Gel
Drug
Lead sponsor
Amzell
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

NCT02596451
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac Sodium gel, 1%, Voltaren® Gel, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
35 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
44
States / cities
Mesa, Arizona • Anaheim, California • Canoga Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Post-Operative Pain Control Following Shoulder Surgery

NCT04622839
View directory record Official record
Conditions
Shoulder Pain
Interventions
Tylenol and NSAIDS (Ibuprofen, diclofenac)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis

NCT01383954
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diclofenac Gel
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 6, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery

NCT00448110
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Diclofenac (DIC075V), Intravenous Ketorolac, placebo
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Florence, Alabama • Montgomery, Alabama + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2009 · Synced Sep 6, 2026, 5:34 AM EDT